{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:04:58Z","timestamp":1791777898261,"version":"4.3.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Previous studies show that dose escalation for gross tumor volume (GTV) improves local control of esophageal cancer (EC). However, optimal boosting remains uncertain. Recently, functional imaging guidance to achieve dose escalation in high-risk areas of tumors has been proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study evaluated the feasibility of dose escalation in tumor regions with high fluorodeoxyglucose (FDG) uptake using intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>\n                      GTV\n                      <jats:sub>PET<\/jats:sub>\n                      was defined as a high FDG uptake region with 50% SUV\n                      <jats:sub>max<\/jats:sub>\n                      threshold for dose escalation. IMRT and IMPT plans were generated for three boosting modes: plan 50.4 (50.4 Gy in clinical target volume, CTV), plan 63 (50.4 Gy in CTV, 63 Gy in GTV), plan 70 (50.4 Gy in CTV, 63 Gy in GTV, and 70 Gy in GTV\n                      <jats:sub>PET<\/jats:sub>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Material:<\/jats:title>\n                    <jats:p>Eleven patients with squamous cell carcinoma were evaluated. Dose parameters for heart, lung, and spinal cord were compared based on the dose-volume histogram (DVH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>\n                      Paired\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test was performed on the doses to organs-at-risk (OARs) among plan 50.4, plan 63, and plan 70 for IMRT and IMPT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Dosimetric parameters for IMRT for heart, lung, and spinal cord increased significantly for plan 63 and some parameters even exceeded dose limits for OARs. Further dose escalation in GTV-PET did not increase dosimetric parameters significantly. Most dosimetric parameters of OARs in IMPT exhibited no statistical change compared with plan 50.4, and doses to OARs were far less than dose constraints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dose escalation by IMRT may lead to increased risk of radiation-related injury. Further dose escalation in high FDG uptake regions did not increase doses to OARs. This dose escalation is ideal for achieving better outcomes for EC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_382_22","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T06:13:21Z","timestamp":1675750401000},"page":"1261-1267","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The feasibility of dose escalation using intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) with FDG PET\/CT guided in esophageal cancer"],"prefix":"10.4103","volume":"18","author":[{"given":"Yiyuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"},{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Radiation Physics, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Physics, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Radiation Physics, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqiu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Physics, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"R1-20250514","first-page":"1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)","volume":"281","author":"Cooper","year":"1999","journal-title":"Radiation Therapy Oncology Group. JAMA"},{"key":"R2-20250514","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/cncr.26586","article-title":"Failure patterns in patients with esophageal cancer treated with definitive chemoradiation","volume":"118","author":"Welsh","year":"2012","journal-title":"Cancer"},{"key":"R3-20250514","doi-asserted-by":"crossref","first-page":"22711","DOI":"10.18632\/oncotarget.8050","article-title":"Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: A phase II study","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"R4-20250514","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13014-019-1249-5","article-title":"A phase I\/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal cancer","volume":"14","author":"Li","year":"2019","journal-title":"Radiat Oncol"},{"key":"R5-20250514","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ijrobp.2010.07.2001","article-title":"Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: A dosimetric study","volume":"81","author":"Welsh","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20250514","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijrobp.2010.10.023","article-title":"Esophageal cancer dose escalation using a simultaneous integrated boost technique","volume":"82","author":"Welsh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20250514","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.radonc.2005.10.017","article-title":"Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer","volume":"77","author":"Chandra","year":"2005","journal-title":"Radiother Oncol"},{"key":"R8-20250514","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.radonc.2008.08.008","article-title":"Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus","volume":"89","author":"Fenkell","year":"2008","journal-title":"Radiother Oncol"},{"key":"R9-20250514","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jamaoncol.2019.2809","article-title":"Results of a phase 1\/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer","volume":"5","author":"Chen","year":"2019","journal-title":"JAMA Oncol"},{"key":"R10-20250514","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1088\/0031-9155\/60\/8\/R155","article-title":"The physics of proton therapy","volume":"60","author":"Newhauser","year":"2015","journal-title":"Phys Med Biol"},{"key":"R11-20250514","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): Final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"key":"R13-20250514","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2014.12.007","article-title":"Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18) FDG-PET\/CT for esophageal cancer","volume":"114","author":"Yu","year":"2015","journal-title":"Radiother Oncol"},{"key":"R14-20250514","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2967\/jnumed.111.092775","article-title":"Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer","volume":"53","author":"Hatt","year":"2012","journal-title":"J Nucl Med"},{"key":"R15-20250514","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.radonc.2010.04.024","article-title":"A systematic review on the role of FDG-PET\/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer","volume":"97","author":"Muijs","year":"2010","journal-title":"Radiother Oncol"},{"key":"R16-20250514","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.radonc.2009.03.006","article-title":"Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18) Fluorodeoxyglucose-PET-CT scan","volume":"91","author":"Aerts","year":"2009","journal-title":"Radiother Oncol"},{"key":"R17-20250514","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2012.03.005","article-title":"The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer","volume":"104","author":"van Elmpt","year":"2012","journal-title":"Radiother Oncol"},{"key":"R18-20250514","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.radonc.2016.08.005","article-title":"Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer","volume":"121","author":"He","year":"2016","journal-title":"Radiother Oncol"},{"key":"R19-20250514","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.ijrobp.2012.01.003","article-title":"Proton beam therapy and concurrent chemotherapy for esophageal cancer","volume":"83","author":"Lin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R20-20250514","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2012.02.015","article-title":"Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer","volume":"84","author":"Lin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R21-20250514","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/cncr.29857","article-title":"Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer","volume":"122","author":"Lin","year":"2016","journal-title":"Cancer"},{"key":"R22-20250514","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2016.01.044","article-title":"An analysis of plan robustness for esophageal tumors: Comparing volumetric modulated arc therapy plans and spot scanning proton planning","volume":"95","author":"Warren","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-20250514","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2008.05.014","article-title":"Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer","volume":"72","author":"Zhang","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-20250514","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4103\/jcrt.JCRT_111_19","article-title":"Implementation of meta-analysis approach, comparing conventional radiotherapy, and proton beam therapy treating head and neck cancer","volume":"16","author":"Shaikh","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R25-20250514","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semradonc.2012.11.002","article-title":"Biological considerations when comparing proton therapy with photon therapy","volume":"23","author":"Paganetti","year":"2013","journal-title":"Semin Radiat Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_382_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:09Z","timestamp":1787067609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_382_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_382_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"2022-02-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}